SS

Sue Susan MacLeman

Ms MacLeman has more than 30 years of experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at Schering-Plough Corporation (now Merck), Amgen, Bristol-Myers Squibb and Mesoblast. Susan has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
RHY
RHY
30/06/24N/AN/A200,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
RHY
RHY
10/10/23
Issued
200,000$0.305$61,000Issue of options